Clinuvel Pharmaceuticals Limited   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Melbourne Australia (1987)

Organization Overview

First Clinical Trial
2007
NCT04053270
First Marketed Drug
2019
afamelanotide (Scenesse)
First NDA Approval
2019
afamelanotide (Scenesse)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

City Clinical Oncology Hospital No 1 | Clinuvel Europe Limited | Clinuvel, Inc. | Clinuvel Pharmaceuticals Limited | CLINUVEL PHARMACEUTICALS LTD | Clinuvel (UK) Ltd. | CLIVUNEL INC

Active Ingredients

Marketed Drugs (1)

afamelanotide (Scenesse) (2019 NDA)

Drugs in Phase 3 Trials (1)

afamelanotide (Scenesse) (21 trials)

Drugs in Phase 2 Trials (1)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Squamous Cell (Phase 2)

Keratosis (Phase 2)

Keratosis, Actinic (Phase 2)

Protoporphyria, Erythropoietic (Phase 3)

Urticaria (Phase 2)

Vitiligo (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 2